52
Participants
Start Date
July 31, 2012
Primary Completion Date
November 30, 2016
Study Completion Date
December 31, 2018
AZD4547 / anastrozole or letrozole
"Patients will continue or restart the NSAI which they have progressed\* on: either anastrozole (1mg) or letrozole (2.5mg), orally, once daily but together with twice daily AZD4547 (80mg).~AZD4547 will be given on an intermittent schedule of one week on / one week off.~\*Prior to study entry, patients must have taken anastrozole or letrozole at some stage in their treatment to date for breast cancer; and shown evidence of resistance to this therapy. The NSAI does not have to be the most recent line of treatment."
Queen's Hospital, Burton-on-Trent, Burton-on-Trent
Russells Hall Hospital, West C8 Admin Office, 2nd Floor, Dudley
Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Breast Cancer Research Unit, PO Box 97, Hills Road,, Cambridge
Greater Glasgow Health Board, Beatson West of Scotland Cancer Centre, 1053 Great Western Road,, Glasgow
Imperial College Healthcare NHS Trust, Charing Cross Hospital,1st Floor, Department of Medical Oncology, Fulham Palace Road, London
The Christie NHS Foundation Trust, Wilmslow Road, Withington, Manchester
The Newcastle upon Tyne Hospitals NHS Foundation Trust, Sir Bobby Robson Cancer Trials Research Centre, Freeman Hospital, High Heaton, Newcastle upon Tyne
Collaborators (2)
Cancer Research UK
OTHER
AstraZeneca
INDUSTRY
Imperial College London
OTHER